Amgen, Inc.  

(Public, NASDAQ:AMGN)   Watch this stock  
Find more results for AMGN
103.78
+1.60 (1.57%)
Real-time:   9:52AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 102.45 - 104.48
52 week 67.61 - 114.95
Open 102.45
Vol / Avg. 161,523.00/4.02M
Mkt cap 77.83B
P/E 17.55
Div/yield 0.47/1.81
EPS 5.91
Shares 749.98M
Beta 0.41
Inst. own 83%
Jul 22, 2013
Q2 2013 Amgen Earnings Release Add to calendar
May 30, 2013
Amgen at Deutsche Bank dbAccess Health Care Conference - 9:20AM EDT - Add to calendar
May 22, 2013
Amgen 2013 Annual Shareholder Meeting Add to calendar
May 21, 2013
Amgen at UBS Global Healthcare Conference - 10:00AM EDT - Add to calendar
Apr 23, 2013
Q1 2013 Amgen Earnings Conference Call
Mar 6, 2013
Amgen at Cowen and Company 33rd Annual Health Care Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '13) 2012
Net profit margin 33.84% 25.17%
Operating margin 34.03% 32.30%
EBITD margin - 52.04%
Return on average assets 10.86% 8.42%
Return on average equity 29.84% 22.81%
Employees 18,000 -
Carbon Disclosure Rating - 75/100

Address

One Amgen Center Drive
THOUSAND OAKS, CA 91320-1799
United States - Map
+1-805-4471000 (Phone)
+1-805-4471010 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha
About Company - Wikipedia
Discussion Group - Google Finance

Description

Amgen Inc. is a global biotechnology pioneer that discovers, develops, manufactures and delivers human therapeutics. Its medicines help millions of patients in the fight against cancer, kidney disease, rheumatoid arthritis (RA), bone disease, and other serious illnesses. On December 10, 2012, the Company acquired all of the outstanding stock of deCODE Genetics (deCODE). In July 5, 2012, the Company acquired KAI Pharmaceuticals, a privately held company based in South San Francisco. In June 12, 2012, the Company acquired substantially all of the outstanding stock of Mustafa Nevzat Pharmaceuticals (MN). In March 7, 2012, the Company acquired Micromet, Inc. (Micromet), a publicly held biotechnology company focused on the discovery, development and commercialization of antibody-based therapies for the treatment of cancer.

Officers and directors

Robert A. Bradway Chairman of the Board, President, Chief Executive Officer
Age: 50
Bio & Compensation  - Reuters
Jonathan M. Peacock Chief Financial Officer, Executive Vice President
Age: 54
Bio & Compensation  - Reuters
Madhavan Balachandran Executive Vice President - Operations
Age: 62
Bio & Compensation  - Reuters
Sean E. Harper Executive Vice President - Research and Development
Age: 50
Bio & Compensation  - Reuters
Anthony C. Hooper Executive Vice President - Global Commercial Operations
Age: 58
Bio & Compensation  - Reuters
Cynthia M. Patton Senior Vice President, Chief Compliance Officer
Age: 51
Bio & Compensation  - Reuters
David J. Scott Senior Vice President, General Counsel, Secretary
Portrait. Age: 60
Bio & Compensation  - Reuters
Brian M. McNamee Senior Vice President - Human Resources
Age: 56
Bio & Compensation  - Reuters
Vance D. Coffman Lead Independent Director
Age: 69
Bio & Compensation  - Reuters
David Baltimore Ph.D. Independent Director
Age: 75
Bio & Compensation  - Reuters